Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Breakthrough for prostate cancer patients as NHS now offers life-extending drug - The new medication is suitable for patients ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Prostate cancer is the second-most common cancer in men. A new study from Thomas Jefferson University uncovered a new ...

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Basel, Switzerland / Munich, Germany, January 26, 2026 - NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that U.S ...

An Alabama Senate bill advances to mandate insurance coverage for prostate cancer screenings, potentially improving early ...

Prostate cancer is the second most commonly diagnosed cancer in men globally, according to the World Health Organisation (WHO ...